Alcon, Inc. has approved a merger agreement with Novartis AG, under which Novartis will pay $12.9 billion for all outstanding Alcon shares. When the merger is complete, Alcon will become the second largest division within Novartis. CIBA Vision and select Novartis ophthalmic medicines will be integrated into Alcon. The organization will have more than $8.7 billion in sales covering approximately 70% of the eye care market. “This merger will create a stronger eye care business with broader com...